Evotec stock holds on to Evotec stock focus

Evotec stock stays supported by the companys latest reported operating context, while the share remains tied to the German biotech groups turnaround metrics and market valuation. Evotec (ISIN DE0005664809) reported revenue of EUR 797.6 million in fiscal 2024, up from EUR 781.7 million in fiscal 2023, and adjusted EBITDA of EUR 22.3 million versus EUR 56.9 million a year earlier.

Revenue at EUR 797.6 million

Revenue rose by EUR 15.9 million year on year in fiscal 2024, a 2.0% increase from fiscal 2023. Adjusted EBITDA fell by EUR 34.6 million over the same period, which shows that the top line moved more steadily than profitability.

The comparison matters for Evotec stock because biotech investors are still judging whether the group can turn modest sales growth into cleaner earnings delivery. The 2024 revenue base and the lower adjusted EBITDA create a clear benchmark for the next report cycle.

EBITDA fell to EUR 22.3 million

Adjusted EBITDA in fiscal 2024 came in at EUR 22.3 million, down from EUR 56.9 million in fiscal 2023. That is a decline of 60.8%, and it remains the clearest profit-side comparison in the latest reported numbers.

The same report framework also showed a weaker earnings profile at the operating level, with the group still dependent on a better cost mix and stronger execution to rebuild margin. For Evotec stock, that makes the next revenue and profit update more important than headline business descriptions.

Product work still matters

In platform terms, Evotec continues to lean on its discovery and development collaborations, which remain the commercial bridge between research activity and recurring revenue. The fiscal 2024 numbers show why that mix matters: EUR 797.6 million in sales is not enough on its own if profit stays at EUR 22.3 million.

That tension is the central story for Evotec stock. The market is likely to keep focusing on whether the company can convert contract activity into steadier earnings momentum rather than only into volume.

Stock value still frames the debate

Without a fresh quoted price in the current session, the best market anchor is the reported fiscal 2024 base and the 60.8% drop in adjusted EBITDA versus fiscal 2023. Those two figures, together with the revenue increase, give investors a dated way to measure whether the next update improves the earnings mix.

Evotec AG is the relevant legal entity for the share, and the companys operating recovery remains the key valuation question behind Evotec stock. The latest reported revenue of EUR 797.6 million and adjusted EBITDA of EUR 22.3 million are the numbers that matter most until the next filing.

Discovery chemistry pipeline

Evotecs business still revolves around discovery chemistry, biologicals, and partner programs for pharmaceutical clients. That makes the companys reported annual revenue and EBITDA especially relevant, because product-level progress only matters for shareholders if it shows up in the P&L.

Market valuation base

Evotec AG is listed in Germany, and the current article frame is built around the latest evidenced annual figures rather than a live quote. For readers tracking Evotec stock, fiscal 2024 revenue of EUR 797.6 million, fiscal 2023 revenue of EUR 781.7 million, and adjusted EBITDA of EUR 22.3 million versus EUR 56.9 million form the most concrete comparison set available here.